Clinical Trial

Immune Response To Intranasal Influenza Vaccination

Active, Not Recruiting

Record status

This record was last updated December 6, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Summary

This research during the last decade has focused on the kinetics of the systemic and local immune response to parenteral influenza vaccine in humans. The investigators have shown that normally high numbers of influenza specific antibody secreting cells (ASC) are present in the nasal mucosa of healthy adults but upon parenteral vaccination the numbers remain stable. However, a rapid transient increase in specific ASC is observed in the tonsils and peripheral blood after parenteral vaccination. In the tonsils, this is associated with a significant decrease in both naïve/effector (CD45RA+) and memory (CD45RO+) CD4+ cells upon vaccination. In this study the investigators will extend our work to investigate the characteristics of influenza-specific T- and B-cells induced locally and systemically after intranasal vaccination in man.

Protocol Amendment History 6 amendments

This ClinicalTrials.gov record has been amended 6 times since 2013-05-28; most recent amendment 2023-12-05.

Status change: Enrolling by Invitation → Active, Not Recruiting 2021-08-01

Status change: Active, Not Recruiting → Enrolling by Invitation 2016-09-19

Status change: Recruiting → Active, Not Recruiting 2014-02-16

Trial Details

NCT Number	NCT01866540
Lead Sponsor	University of Bergen Collaborators: Haukeland University Hospital
Conditions	Tonsillitis, Hypertrophy
Enrollment	300 participants
Start Date	2012-10-01
Primary Completion	2025-12-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2023-12-06